{"raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe IC50 values for BRAF and RAF1 (CRAF) kinases by Compound 1 were measured, resulting in IC50 values of 5.98 nM and 1.3 nM, respectively, as indicated in Table 1.\nTABLE 1IC50SEMKinase(nM)n(nM)BRAF5.98170.51RAF1 (CRAF)1.3\u2002180.05"}
{"final_json": [{"molecule_name": "Compound 1", "protein_target_name": "BRAF", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "IC50", "value": "5.98", "unit": "nM"}, {"molecule_name": "Compound 1", "protein_target_name": "RAF1 (CRAF)", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "IC50", "value": "1.3", "unit": "nM"}]}
{"raw_mentions": "Compound 1 was demonstrated to be a potent inhibitor of the RAF1, BRAF, ARAF kinases, with IC50 values <5 nM.\nKinases outside the RAF family inhibited >10% by 1 \u03bcM Compound 1 are listed in Table 3."}
{"final_json": [{"molecule_name": "Compound 1", "protein_target_name": "RAF1, BRAF, ARAF kinases", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "IC50", "value": "<5", "unit": "nM"}, {"molecule_name": "Compound 1", "protein_target_name": "Kinases outside the RAF family", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": ">10", "unit": "%"}]}
{"raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nHSAMost synergistic area score 21.6(binimetinib: 31.2-500 nM;compound 1: 111.1-1000 nM)\nLoeweMost synergistic area score 16.2(binimetinib: 7.8-125 nM;compound 1: 37-333.3 nM)\nBlissMost synergistic area score 11.6(binimetinib: 7.8-125 nM;compound 1: 12.3-111.1 nM)"}
{"final_json": [{"molecule_name": "binimetinib", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "Concentration", "value": "31.2-500", "unit": "nM"}, {"molecule_name": "compound 1", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "Concentration", "value": "111.1-1000", "unit": "nM"}, {"molecule_name": "binimetinib", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "Concentration", "value": "7.8-125", "unit": "nM"}, {"molecule_name": "compound 1", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "Concentration", "value": "37-333.3", "unit": "nM"}, {"molecule_name": "binimetinib", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "Concentration", "value": "7.8-125", "unit": "nM"}, {"molecule_name": "compound 1", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "Concentration", "value": "12.3-111.1", "unit": "nM"}]}
{"raw_mentions": "None of the provided sentences or table rows contain all of the required elements: a bioactivity metric (IC50, Ki, Kd, EC50), a specific numeric value associated with that metric, and a unit for that value. The text primarily discusses tumor growth inhibition (TGI) percentages, treatment doses in mg/kg, and tumor volumes in mm^3, but does not include the specified bioactivity metrics with their respective values and units."}
{"raw_mentions": "Here are the extracted sentences with concrete data points that meet the specified criteria:\n\n\nNone of the sentences in the provided text contain all three required elements: a bioactivity metric (IC50, Ki, Kd, EC50), a specific numeric value associated with that metric, and a unit for that value."}
{"raw_mentions": "There are no sentences that meet the specified criteria. The text does not contain any sentences with a bioactivity metric (IC50, Ki, Kd, EC50), a specific numeric value, and a unit for that value."}
